{"title":"Clinical efficacy and safety of sintilimab injection plus chemotherapy in patients with stage IB-IIIB non-small cell lung cancer.","authors":"Qiang Guo, Haijun Wang, Yanzhao Xu, Mingbo Wang, Ziqiang Tian","doi":"10.12669/pjms.41.3.9830","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To investigate the clinical efficacy of sintilimab injection and chemotherapy as neoadjuvant therapy for stage IB-IIIB non-small cell lung cancer(NSCLC), and evaluate its clinical safety.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on the clinical data of patients with stage IB-IIIB NSCLC who underwent neoadjuvant treatment before surgery at Affiliated Hospital of Hebei University, between June 2021 to August 2023. Eighty patients were divided into an observation group(n = 40) and a control group(n = 40) according to their treatment regimens. The control group was administered albumin-bound paclitaxel plus cisplatin, while the observation group received sintilimab injection in addition to the exact treatment provided for the control group. The clinical efficacy, tumor marker levels, immune function, and quality of life were compared between the two groups.</p><p><strong>Results: </strong>After treatment, the overall response rate in the observation group was 85.00%, significantly higher than 65.00% in the control group(P< 0.05). The overall pathological response rate in the observation group was 77.5%, significantly higher than 42.5% in the control group (P< 0.05).During treatment, adverse reactions were observed in both groups. Yet, there was no statistically significant difference in the incidence of adverse drug reactions between the two groups (P > 0.05).</p><p><strong>Conclusion: </strong>The combination therapy of sintilimab injection, albumin-bound paclitaxel, and cisplatin for stage IB-IIIB NSCLC can effectively reduce tumor marker levels, improve immune function, demonstrating favorable clinical and pathological efficacy without increasing the incidence of adverse drug reactions.</p>","PeriodicalId":19958,"journal":{"name":"Pakistan Journal of Medical Sciences","volume":"41 3","pages":"724-729"},"PeriodicalIF":1.2000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11911739/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pakistan Journal of Medical Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.12669/pjms.41.3.9830","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To investigate the clinical efficacy of sintilimab injection and chemotherapy as neoadjuvant therapy for stage IB-IIIB non-small cell lung cancer(NSCLC), and evaluate its clinical safety.
Methods: A retrospective analysis was conducted on the clinical data of patients with stage IB-IIIB NSCLC who underwent neoadjuvant treatment before surgery at Affiliated Hospital of Hebei University, between June 2021 to August 2023. Eighty patients were divided into an observation group(n = 40) and a control group(n = 40) according to their treatment regimens. The control group was administered albumin-bound paclitaxel plus cisplatin, while the observation group received sintilimab injection in addition to the exact treatment provided for the control group. The clinical efficacy, tumor marker levels, immune function, and quality of life were compared between the two groups.
Results: After treatment, the overall response rate in the observation group was 85.00%, significantly higher than 65.00% in the control group(P< 0.05). The overall pathological response rate in the observation group was 77.5%, significantly higher than 42.5% in the control group (P< 0.05).During treatment, adverse reactions were observed in both groups. Yet, there was no statistically significant difference in the incidence of adverse drug reactions between the two groups (P > 0.05).
Conclusion: The combination therapy of sintilimab injection, albumin-bound paclitaxel, and cisplatin for stage IB-IIIB NSCLC can effectively reduce tumor marker levels, improve immune function, demonstrating favorable clinical and pathological efficacy without increasing the incidence of adverse drug reactions.
期刊介绍：
It is a peer reviewed medical journal published regularly since 1984. It was previously known as quarterly "SPECIALIST" till December 31st 1999. It publishes original research articles, review articles, current practices, short communications & case reports. It attracts manuscripts not only from within Pakistan but also from over fifty countries from abroad.
Copies of PJMS are sent to all the import medical libraries all over Pakistan and overseas particularly in South East Asia and Asia Pacific besides WHO EMRO Region countries. Eminent members of the medical profession at home and abroad regularly contribute their write-ups, manuscripts in our publications. We pursue an independent editorial policy, which allows an opportunity to the healthcare professionals to express their views without any fear or favour. That is why many opinion makers among the medical and pharmaceutical profession use this publication to communicate their viewpoint.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
